# Novartis Pharmaceuticals Corporation, East Hanover, NJ – FDA Inspections

Source: https://www.keypedia.com/companies/novartis-pharmaceuticals-corporation/aa4c85c1-794a-407a-8eb3-8802c196795b

> Inspection records and compliance data for Novartis Pharmaceuticals Corporation in East Hanover, New Jersey. 31 FDA inspections on record, 4 Form 483s, last inspected June 24, 2026.

---

## Details

- Name: Novartis Pharmaceuticals Corporation
- FEI Number: 2210396
- Address Line 1: 1 Health Plz
- City: East Hanover
- State: New Jersey
- Zip Code: 07936
- Country Name: United States
- Address: 1 Health Plz, East Hanover, New Jersey 07936, United States
- Country: United States

## Related Documents

- FDA Inspection 1328008 - Novartis Pharmaceuticals Corporation - 2026-06-24 — source: FDA, date: June 24, 2026
- FDA Inspection 1276202 - Novartis Pharmaceuticals Corporation - 2025-06-25 — source: FDA, date: June 25, 2025
- [FDA Inspection 1276202 - Novartis Pharmaceuticals Corporation - 2025-06-25](https://www.keypedia.com/records/fda_inspections/novartis-pharmaceuticals-corporation/d76eeb82-f498-4fa6-9c50-25c0625a0d59) — classification: No Action Indicated (NAI), source: FDA, date: June 25, 2025
- FDA Inspection 1263198 - Novartis Pharmaceuticals Corporation - 2025-03-03 — source: FDA, date: March 3, 2025
- FDA Inspection 1263198 - Novartis Pharmaceuticals Corporation - 2025-03-03 — classification: No Action Indicated (NAI), source: FDA, date: March 3, 2025
- FDA Inspection 1257911 - Novartis Pharmaceuticals Corporation - 2024-11-19 — source: FDA, date: November 19, 2024
- FDA Inspection 1257911 - Novartis Pharmaceuticals Corporation - 2024-11-19 — classification: No Action Indicated (NAI), source: FDA, date: November 19, 2024
- [FDA Inspection 1248433 - Novartis Pharmaceuticals Corporation - 2024-08-29](https://www.keypedia.com/records/fda_inspections/novartis-pharmaceuticals-corporation/ccf044c3-0b3e-481e-97b9-66c1a8ca3e62) — classification: No Action Indicated (NAI), source: FDA, date: August 29, 2024
- FDA Inspection 1230105 - Novartis Pharmaceuticals Corporation - 2024-06-27 — classification: No Action Indicated (NAI), source: FDA, date: June 27, 2024
- [483 - Novartis Pharmaceuticals Corporation - 2023-08-21](https://www.keypedia.com/records/483/novartis-pharmaceuticals-corporation/b86a870b-4f00-4ca2-a2ea-f19029e24813) — source: FDA, date: August 21, 2023
- [FDA Inspection 1215374 - Novartis Pharmaceuticals Corporation - 2023-08-21](https://www.keypedia.com/records/fda_inspections/novartis-pharmaceuticals-corporation/b58d0339-4531-411e-9cc4-b4ca576ddf97) — classification: Voluntary Action Indicated (VAI), source: FDA, date: August 21, 2023
- [483 - Novartis Pharmaceuticals Corporation - 2018-12-14](https://www.keypedia.com/records/483/novartis-pharmaceuticals-corporation/fbb8db5f-8a5a-4601-9915-315db47dee65) — source: FDA, date: December 14, 2018
- [EIR - Novartis Pharmaceuticals Corporation - 2017-09-07](https://www.keypedia.com/records/eir/novartis-pharmaceuticals-corporation/faf8091c-3829-4500-a76d-e0a68515ed42) — source: FDA, date: September 7, 2017
- [EIR - Novartis Pharmaceuticals Corporation - 2017-03-02](https://www.keypedia.com/records/eir/novartis-pharmaceuticals-corporation/4b8966de-a19c-48ea-91fb-d06761d6856a) — source: FDA, date: March 2, 2017
- [EIR - Novartis Pharmaceuticals Corporation - 2017-01-24](https://www.keypedia.com/records/eir/novartis-pharmaceuticals-corporation/f6b0814a-9c3b-48e4-a46d-b85c65a0df9e) — source: FDA, date: January 24, 2017
- [483 - Novartis Pharmaceuticals Corporation - 2017-01-24](https://www.keypedia.com/records/483/novartis-pharmaceuticals-corporation/4337d8c5-ec9f-4ec5-9878-9d9925dbaf1b) — source: FDA, date: January 24, 2017
- [483 - Novartis Pharmaceuticals Corporation - 2014-08-05](https://www.keypedia.com/records/483/novartis-pharmaceuticals-corporation/7b7960f8-08c8-49f2-a0bc-275ee2905eaa) — source: FDA, date: August 5, 2014

## Related Companies

- [Consumer Product Testing Co. Inc.](https://www.keypedia.com/companies/consumer-product-testing-co-inc/2e8a54eb-fe3b-41f8-9bd5-b47584e96221)
- [Chartwell Pharmaceuticals West Caldwell LLC](https://www.keypedia.com/companies/chartwell-pharmaceuticals-west-caldwell-llc/b2b85c90-5235-447f-a2ce-36cf51c7d0f1)
- [Bennett Testing Service, Inc.](https://www.keypedia.com/companies/bennett-testing-service-inc/16765b51-2b93-41db-8c4b-077e856d8dc9)
- [Chromak Research Inc](https://www.keypedia.com/companies/chromak-research-inc/e7eccd52-0e4f-4a4c-81e6-7331d2a64609)
- [Element Materials Technology Ann Arbor, LLC](https://www.keypedia.com/companies/element-materials-technology-ann-arbor-llc/84b936d0-5231-4925-b094-8515ab19bdcf)
- [PETNET Solutions Inc](https://www.keypedia.com/companies/petnet-solutions-inc/e4b295dd-c782-487d-9407-3fcfe4e9f9f1)
- [Element Materials Technology Midland Inc.](https://www.keypedia.com/companies/element-materials-technology-midland-inc/a0ed9eaa-521f-4bfe-80b2-309354e62271)
- [Spectral Data Services, Inc.](https://www.keypedia.com/companies/spectral-data-services-inc/d57ed517-a7fb-4a66-8a76-22de97b65f54)
- [Elemental Analysis, Inc.](https://www.keypedia.com/companies/elemental-analysis-inc/29307a33-c2b2-4ddf-ae7b-7c76e84cfce8)
- [Eurofins PROXY Laboratories B.V.](https://www.keypedia.com/companies/eurofins-proxy-laboratories-bv/f285c14e-3524-4cb3-8bd8-767736fdfa78)

## Related Officers

- [investigator](https://www.keypedia.com/people/christina-n-maurino/83a10358-7da6-47e9-8f90-094f81991b86)
- [company_representative](https://www.keypedia.com/people/helen-doster/15c70de3-7324-4908-87f8-a42481682864)
- [company_representative](https://www.keypedia.com/people/john-esposito/30bb5f03-eba4-4bb9-8ced-6177984e15f5)
- [Regulatory Officer](https://www.keypedia.com/people/peter-r-lenahan/c695dac2-5447-434b-801e-f95e6acf05f1)
- [investigator](https://www.keypedia.com/people/nina-yang/8d080437-2e05-4b75-8c53-b818d761cf1f)
